Dr. Nigel Stevenson from Exubrion Therapeutics® and Vivos Inc. CEO and President Dr. Mike Korenko have submitted a joint abstract entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and Osteoarthritis” to the 11th International Conference on Isotopes on July 23-24 in Saskatoon Canada.
Nigel is Exubrion Therapeutics’ Chief Operations Officer and is also the Vivos Inc. Chief Science Advisor. The two companies co-operate since they are in totally different therapy markets. The executives of both companies decided that it is in their best interest to promote the benefits of precision radionuclide therapy.
Dr. Nigel Stevenson
Dr. Mike Korenko
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
Write a comment